162 related articles for article (PubMed ID: 19606707)
21. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
22. Regression of Hodgkin lymphoma after discontinuation of a tumor necrosis factor inhibitor for Crohn's disease: a case report and review of the literature.
Cassaday RD; Malik JT; Chang JE
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):289-92. PubMed ID: 21658658
[TBL] [Abstract][Full Text] [Related]
23. Sarcoidosis complicating treatment with adalimumab for Crohn's disease.
McDonnell MJ; Rutherford RM; O'Regan A
J Crohns Colitis; 2014 Sep; 8(9):1140-1. PubMed ID: 24631310
[No Abstract] [Full Text] [Related]
24. Esophageal Crohn's disease treated successfully with adalimumab.
Kwan LY; Conklin JL; Papadakis KA
Inflamm Bowel Dis; 2007 May; 13(5):639-40. PubMed ID: 17221856
[No Abstract] [Full Text] [Related]
25. Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab.
Mañosa M; Domènech E; Marín L; Olivé A; Zabana Y; Cabré E; Gassull MA
Gut; 2008 Apr; 57(4):559; author reply 559-60. PubMed ID: 18334664
[No Abstract] [Full Text] [Related]
26. Guillain-Barrè syndrome after treatment with human anti-tumor necrosis factorα (adalimumab) in a Crohn's disease patient: case report and literature review.
Cesarini M; Angelucci E; Foglietta T; Vernia P
J Crohns Colitis; 2011 Dec; 5(6):619-22. PubMed ID: 22115384
[TBL] [Abstract][Full Text] [Related]
27. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease.
Riis A; Martinsen TC; Waldum HL; Fossmark R
Scand J Gastroenterol; 2012 Jun; 47(6):649-57. PubMed ID: 22472026
[TBL] [Abstract][Full Text] [Related]
28. Adalimumab for recurrent orbital myositis in Crohn's disease: report of a case with a 3-year follow-up.
Hernández-Garfella ML; Gracia-García A; Cervera-Taulet E; García-Villanueva C; Montero-Hernández J
J Crohns Colitis; 2011 Jun; 5(3):265-6. PubMed ID: 21575896
[No Abstract] [Full Text] [Related]
29. Multiple and fulminant cutaneous squamous cell carcinomas in a Crohn's disease patient treated with immunosuppressants and adalimumab.
Nancey S; Boschetti G; Cotte E; Cathey-Javouhay A; Laidet M; Chichery A; Francois Y; Glehen O; Flourié B
Inflamm Bowel Dis; 2011 Apr; 17(4):1060-1. PubMed ID: 21391289
[No Abstract] [Full Text] [Related]
30. [The use of adalimumab in severe fistulising Crohn's disease].
Bang UC; Nielsen AM
Ugeskr Laeger; 2008 Jun; 170(25):2256. PubMed ID: 18565318
[TBL] [Abstract][Full Text] [Related]
31. [Adalimumab therapy in Crohn's disdease].
Baryshnikov EN; Lazebnik LB; Parfenov AI
Eksp Klin Gastroenterol; 2009; (5):92-8. PubMed ID: 20205331
[TBL] [Abstract][Full Text] [Related]
32. [Adalimumab in Crohn's disease - data from real life].
López San Román A; Van Domselaar M; Garrido E
Rev Esp Enferm Dig; 2008 Nov; 100(11):671-5. PubMed ID: 19159169
[No Abstract] [Full Text] [Related]
33. Fulminant Crohn's colitis: when only an antibody will do.
Ng SC; Kamm MA
Inflamm Bowel Dis; 2007 Aug; 13(8):971-4. PubMed ID: 17427240
[TBL] [Abstract][Full Text] [Related]
34. Severe myalgia associated with adalimumab treatment in a patient with Crohn's disease.
Hinojosa J; Borrás-Blasco J; Maroto N; Rosique-Robles JD; Alos R; Casterá ME
Ann Pharmacother; 2008 Jul; 42(7):1130-3. PubMed ID: 18492783
[TBL] [Abstract][Full Text] [Related]
35. [Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease].
Veres G; Putz R; Szabó D; Molnár K; Bodánszky H; Dezsofi A; Arató A
Orv Hetil; 2009 Oct; 150(40):1858-60. PubMed ID: 19789146
[TBL] [Abstract][Full Text] [Related]
36. [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].
Sansó Sureda A; Rocamora Durán V; Sapiña Camaró A; Royo Escosa V; Bosque López MJ
Gastroenterol Hepatol; 2011 Oct; 34(8):546-50. PubMed ID: 21665330
[TBL] [Abstract][Full Text] [Related]
37. Atypical mycobacteria: showerheads, anti-TNF therapy and Crohn's disease.
Desai AA; Marks DJ
Expert Rev Clin Immunol; 2010 Sep; 6(5):695-9. PubMed ID: 20828275
[No Abstract] [Full Text] [Related]
38. Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.
Martín-de-Carpi J; Pociello N; Varea V
J Crohns Colitis; 2010 Nov; 4(5):594-8. PubMed ID: 21122566
[TBL] [Abstract][Full Text] [Related]
39. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
[TBL] [Abstract][Full Text] [Related]
40. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
